文献速递甲状腺疾病

甲状腺癌脑转移的放疗:一项机构内与国家回顾性队列研究

Radiotherapy for Brain Metastases from Thyroid Cancer: An Institutional and National Retrospective Cohort Study.
PubMed 文献 · Thyroid · 2022-06-06

该研究纳入2002至2020年在本机构接受放疗的33例甲状腺癌脑转移患者(共212个病灶),并分析国家癌症数据库(NCDB)中289例患者。本机构队列总生存期为6.6个月,1年局部失败累积 incidence 为7.0%,1年颅内远处失败为38%,放射性坏死风险为3.3%;NCDB队列中位生存期为10.2个月,立体定向放射外科(SRS)使用率随时间增加。作者结论认为SRS安全有效且应成为标准治疗。

要点

  • 本机构33例甲状腺癌脑转移患者接受放疗,总生存期6.6个月。
  • 1年局部失败累积 incidence 7.0%,颅内远处失败38%,放射性坏死风险3.3%。
  • NCDB中289例患者中位生存期10.2个月,SRS使用率随时间增加。

核心结论

  • 作者结论认为SRS对任何组织学类型的甲状腺癌脑转移均安全、有效且使用日益增多,应成为标准治疗。

研究设计与样本

  • 机构内回顾性队列纳入2002至2020年接受放疗的甲状腺癌脑转移患者33例(212个病灶)。
  • NCDB国家回顾性队列纳入289例甲状腺癌脑转移接受脑部放疗的患者。

主要发现

  • 机构内队列总生存期为6.6个月,1年局部失败累积 incidence 为7.0%,1年颅内远处失败为38%。
  • 机构内队列1年放射性坏死风险为3.3%。
  • NCDB队列中位生存期为10.2个月,全国实践模式分析显示整个队列及间变性患者亚组中SRS使用随时间增加。

关键数值与推荐

  • 机构内队列1年局部失败累积 incidence 7.0%,1年颅内远处失败38%,1年放射性坏死风险3.3%。
  • NCDB队列中位生存期10.2个月。
  • 对总生存、局部失败风险、区域颅内失败风险和放射性坏死风险进行了单变量分析。

临床怎么用

  • 作者结论认为SRS应成为甲状腺癌脑转移的标准治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Stereotactic radiosurgery (SRS) is the standard of care for patients with a limited number of brain metastases. Despite the fact that the seminal studies regarding SRS for brain metastases were largely tissue agnostic, several current national guidelines do not uniformly recommend SRS in thyroid cancer. We therefore investigated oncological outcomes in a cohort of patients with brain metastases from thyroid cancer who received radiotherapy (RT) at our institution as well as those in a nationally representative cancer cohort, the National Cancer Database (NCDB). Materials and Methods: We identified patients with thyroid cancer and brain metastases treated with RT at our institution from 2002 through 2020. For the NCDB cohort, the national database of patients with thyroid cancer was screened on the basis of brain-directed RT or brain metastases. For the institutional cohort, the cumulative risk of local failure (LF), distant intracranial failure, and radiation necrosis were calculated, adjusted for the competing risk of death. Overall survival (OS) in both cohorts was analyzed using the Kaplan-Meier method. Univariate analysis was accomplished via clustered competing risks regression. Results: For the institutional cohort, we identified 33 patients with 212 treated brain metastases. OS was 6.6 months. The 1-year cumulative incidences of LF and distant intracranial failures were 7.0% and 38%, respectively. The 1-year risk of radiation necrosis was 3.3%. In the NCDB cohort, there were 289 patients, and the median survival was 10.2 months. NCDB national practice patterns analysis showed an increasing use of SRS over time in both the entire cohort and the subset of anaplastic patients. Univariate analysis was performed for OS, risk of LF, risk of regional intracranial failure, and risk of radiation necrosis. Conclusions: SRS is a safe, effective, and increasingly utilized treatment for thyroid cancer brain metastases of any histology and should be the standard of care treatment.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Blomain E, Berta S, Hug N, et al. Radiotherapy for Brain Metastases from Thyroid Cancer: An Institutional and National Retrospective Cohort Study. Thyroid. 2022. PMID: 35229625. doi:10.1089/thy.2021.0628

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。